1. Market Research
  2. > Biotechnology Market Trends
  3. > Nanoparticles in Biotechnology, Drug Development and Drug Delivery

This BCC Research report provides detailed product analyses within health and wellness subsegments to overall industry trends in order to quantify and qualify the market for drug products for treating various disease conditions in both men and women. The applicability of specific types of nanoparticles for specific applications is also discussed. CAGR projections are given from the period 2014 through 2019.

Use this report to:
- Receive a range of information, from detailed product analyses within health and wellness subsegments to overall industry trends in order to quantify and qualify the
market for drug products for treating various disease conditions in both men and women.
- Receive information on specific classes of nanoparticles and the pharmaceutical products associated with them.
- Examine competitive environment with a special focus on how new products will alter the quality of life of patients receiving nanoparticle-associated drugs.
- Learn about the major licensing, collaborative partnerships and, merger and acquisition activities in the industry.

Highlights
- The global market for nanoparticles in biotechnology and pharmaceuticals reached nearly $25.0 billion in 2013. This market is expected to reach $29.6 billion in 2014 and $79.8 billion in 2019, with a compound annual growth rate (CAGR) of 22.0% for the period of 2014 to 2019.
- Drug delivery systems as a segment is projected to increase from nearly $15.8 billion in 2014 to $44.5 billion by 2019, with a CAGR of 23.0% for the period of 2014 to 2019.
- Drug development and formulation as a segment is projected to increase from nearly $12.6 billion in 2014 to $32.3 billion by 2019, with a CAGR of 20.8% for the period of 2014 to 2019.

INTRODUCTION

STUDY GOALS AND OBJECTIVES
This study provides a comprehensive analysis of the market for nanoparticles in the life sciences on a global basis. Particular attention is given to drug development, formulation and the development of new drug delivery systems. Its aim is to provide a range of information, from detailed product analyses within health and wellness
subsegments to overall industry trends in order to quantify and qualify the market for drug products for treating various disease conditions in both men and women. The
applicability of specific types of nanoparticles for specific applications is discussed. Forecasts and trends are developed from a cross-reference of data points gleaned from
proprietary industry sources, company publications, industry benchmarking and other divergent data sources to arrive at a cogent and coordinated forecast.

REASONS FOR DOING THE STUDY
For companies with an effective strategy, market opportunities await. Importantly, the ability to develop an effective strategy begins with knowing where opportunity exists
and ends with a plan to effectively execute in order to capture profit from opportunity. The nanoparticle drug/delivery market presents an increasingly significant part of the
overall pharmaceutical product market worldwide. This study investigates the specific classes of nanoparticles and the pharmaceutical products associated with them.
Existing drug products and potential drugs in the pipelines of the major pharmaceutical players in this market are reviewed. Growing health concerns in developing countries
are expected to continue to contribute substantially to market growth through the forecast period (2014 through 2019). This report analyzes emerging markets by
technology category. Continued growth is expected in emerging geographies driven by the health awareness of the growing middle class in emerging countries such as India,
China, Brazil and Russia. This report seeks to address the critically important topics of analyzing a changing market dynamic, emerging players and products, strategies for accessing emerging markets and awareness of specific disease prevalence and geographies thereof in order to allocate resources and make effective decisions.

SCOPE OF REPORT
Current and projected product forecasts during the forecast period of 2014 through 2019 are discussed. New product launches will be discussed. Revenue figures for 2013 are actual figures except where actual results have not been reported due to the timing of this report’s release. The report includes analysis of leading and emerging drug products for each nanoparticle type. Profiles of manufacturers of leading products and their specific products are provided. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products will alter the quality of life of patients receiving nanoparticle-associated drugs. Market figures are based on revenues at the manufacturer level and are projected at 2013-dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, for new product introductions, expanded markets for existing products and other factors affecting the market.

Included in this report are forecasts by product, product category and by company from 2012 through 2019. The study is arranged to offer an overview of existing nanoparticle technology and of drug markets; it is accompanied by nanoproduct, company, geography and mechanism of action, with forecasts broken down and covered by geographic region or country. Patent and clinical trial information is reviewed for various candidate nanodrugs. The status of approvals of drugs in each segment by the FDA and regulatory agencies in other countries is reviewed. Figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies. All market share data presented is on a global basis unless specifically noted.

INTENDED AUDIENCE
This report is an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investors, investor consultants and anyone interested in the nanoparticle drug market, its products, its industry participants and its future. The importance of identifying overall market trends, product opportunities, emerging geographies, merger and acquisition (M&A) opportunities, and insights that provide guidance for sales growth or defensive moves cannot be overstated for a variety of constituents, including:

- Established companies in the industry shall benefit from the contents, including corporate strategy, sales and marketing, business development and R&D.
- Emerging players in the segment must understand specific opportunities for out-licensing originating from the elements of differentiation of their product or technology as compared to leading, competitive and emerging products. As well, market forecasts can support investment; thorough and detailed substantiation is provided for the market forecast in this study.
- Investment firms evaluating candidates for venture capital or hedged investments will gain insights as to the opportunities and risks that are being encountered in the
industry in a product- and company-specific analysis.
- Equity analysts are provided detailed forecasts for the next five years, substantiated by quantitative analysis that can support further analysis to product and company forecasts over the short and long run.

METHODOLOGY AND INFORMATION SOURCES
In-depth interviews were conducted with leading experts in the field who are executives in companies, industry analysts and leading individuals in the field. The nanoparticle biomedical technology market is comprised of drug products for treatment of an assortment of specific diseases of both men and women. For completeness, the current and forecasted markets are comprised of the total market opportunity for each respective segment. Within each subsection, there are detailed forecasts for each driving mechanism or relevant area of growth. Information to prepare this report was obtained from participating and emerging companies in the nanoparticle area and from the National Institute of Kidney and Urologic Diseases Information Clearinghouse (NKUDIC), a service of Nat. Inst. of Diabetes and Digestive and Kidney Diseases (NIDDK), National Library of Medicine (NLM, NIH).

Additional information was obtained from a variety of medical and technical journals in the various specialties of the nanoparticle applications. Other sources include: the New York Times, Wall Street Journal, Washington Post, other newspapers, company documents and other websites. Population estimates are based on those reported by the International database of the U.S. Census Bureau. Statistical data was obtained from the World Health Organization (WHO), National Institute of Health (NIH) and WHO Collaborating Centre for Drug Statistics Methodology (Norway). Current and historical revenue figures for individual products have been sourced from company disclosures that exist in the public domain or from government sources.

Table Of Contents

Nanoparticles in Biotechnology, Drug Development and Drug Delivery
TABLE OF CONTENTS
CHAPTER 1 INTRODUCTION 2
STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THE STUDY 2
SCOPE OF REPORT 2
INTENDED AUDIENCE 3
METHODOLOGY AND INFORMATION SOURCES 4
ANALYST'S CREDENTIALS 4
RELATED BCC RESEARCH REPORTS 4
BCC RESEARCH WEBSITE 5
DISCLAIMER 5
CHAPTER 2 SUMMARY 7
SUMMARY TABLE GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND
PHARMACEUTICALS, THROUGH 2019 ($ MILLIONS) 8
SUMMARY FIGURE GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY
AND PHARMACEUTICALS, 2012-2019 ($ MILLIONS) 8
CHAPTER 3 OVERVIEW 11
NANOPARTICLE OVERVIEW 11
TABLE 1 DESCRIPTION OF NANOPARTICLES USED IN DRUG DELIVERY AND
DIAGNOSTIC IMAGING 12
LIPOSOMES 13
QUANTUM DOTS 13
DENDRIMERS 13
MACROMOLECULE NANOPARTICLES 13
BRIEF HISTORY OF NANOPARTICLES 14
NANOPARTICLES IN BIOTECHNOLOGY 14
TABLE 2 APPLICATION OF NANOPARTICLES IN BIOTECHNOLOGY 15
NANOPARTICLES IN DRUG DEVELOPMENT 15
TABLE 3 APPLICATION OF NANOPARTICLES IN DRUG DEVELOPMENT 16
NANOPARTICLES IN DRUG DELIVERY SYSTEMS 16
TABLE 4 APPLICATION OF NANOPARTICLES IN DRUG DELIVERY SYSTEMS 17
TABLE 5 NANOPARTICLE DRUG DELIVERY SYSTEMS 18
NANOPARTICLES IN DIAGNOSTIC IMAGING 19
TABLE 6 NANOPARTICLES USED FOR IN VIVO DIAGNOSTIC IMAGING 20
MAJOR PLAYERS IN NANOPARTICLE DRUG DELIVERY FIELD 20
TABLE 7 MAJOR PLAYERS IN NANOPARTICLE DRUG FIELD 21
TABLE 8 MAJOR PLAYER COMPANY REVENUES FOR NANOPARTICLE DRUGS,
THROUGH 2019 ($ MILLIONS) 22
MAJOR NANOPARTICLE/NANOCRYSTAL DRUG REVENUES 23
TABLE 9 MAJOR NANOPARTICLE/NANOCRYSTAL DRUG REVENUES, THROUGH 2014 23
CHAPTER 4 GLOBAL MARKET FOR NANOPARTICLES IN LIFE SCIENCE 25
TABLE 10 GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND
PHARMACEUTICALS, THROUGH 2019 ($ MILLIONS) 25
GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY 25
TABLE 11 GLOBAL REVENUES BIOTECHNOLOGY APPLICATIONS OF
NANOPARTICLES, THROUGH 2019 ($ MILLIONS) 26
GLOBAL MARKET FOR NANOPARTICLES IN DRUG DEVELOPMENT 26
TABLE 12 GLOBAL MARKET FOR NANOPARTICLES IN DRUG DEVELOPMENT AND
FORMULATION, THROUGH 2019 ($ MILLIONS) 27
GLOBAL MARKET FOR NANOPARTICLES IN DRUG DELIVERY SYSTEMS 27
TABLE 13 GLOBAL REVENUES FROM NANOPARTICLES IN DRUG DELIVERY SYSTEMS,
THROUGH 2019 ($ MILLIONS) 28
GLOBAL MARKET FOR NANOPARTICLES IN DIAGNOSTIC IMAGING 28
TABLE 14 GLOBAL REVENUES FROM NANOPARTICLES IN DIAGNOSTIC IMAGING
SYSTEMS, THROUGH 2019 ($ MILLIONS) 29
GLOBAL DISTRIBUTION OF NANOBIOTECHNOLOGY AND NANOMEDICINE
COMPANIES 29
TABLE 15 GLOBAL DISTRIBUTION OF NANOBIOTECHNOLOGY AND NANOMEDICINE
COMPANIES 29
CHAPTER 5 NANOPARTICLES STRUCTURE 33
ADOPTION OF NANOPARTICLES IN APPLIED MARKETS 33
TABLE 16 NANOPARTICLE STRUCTURE AND PROPERTIES 33
LIQUID CRYSTALS 34
LIQUID CARRIERS 34
LIPOSOMES 34
DENDRIMERS 35
CHITOSAN AND ALGINATE 35
NANOCRYSTALS 35
QUANTUM DOTS 36
APPLICATION OF NANOPARTICLES TO DRUGS DELIVERED 37
TABLE 17 NANOPARTICLE SYSTEMS APPROVED FOR DRUG DELIVERY 37
CHAPTER 6 NANOPARTICLE PRODUCTION 40
METHOD OF NANOPARTICLE FORMATION 40
SELF-ASSEMBLY PRODUCTION 41
METHODS OF STABILIZATION 42
METHODS OF DRUG INTRODUCTION 42
POLYMERIC NANOPARTICLES 42
MICELLES 43
LIPOSOMES 43
TABLE 18 SAMPLE OF DRUGS DELIVERED THROUGH LIPOSOME
NANOTECHNOLOGY 43
GOLD AND SILICON NANOPARTICLES 44
DENDRIMERS 44
METHODS OF LOADING BIOLOGICAL MOLECULES INTO NANOPARTICLES 45
NANOCRYSTAL DRUGS 45
PROBLEMS WITH LARGE-SCALE NANOPARTICLE PRODUCTION 46
CHAPTER 7 NANOPARTICLES IN BIOTECHNOLOGY 49
TABLE 19 NANOPARTICLES IN BIOTECHNOLOGY APPLICATIONS 49
RESEARCH AND DEVELOPMENT 50
STEM CELL RESEARCH 50
CELLULAR REPAIR 51
IN VITRO IMAGING 52
PARAMAGNETIC AND SUPERPARAMAGNETIC NANOPARTICLES 53
BIOSENSORS AND QUANTUM DOTS 53
QUANTUM DOTS 53
BIOSENSORS 54
TABLE 20 NANOBIOSENSOR TECHNOLOGY UNDER DEVELOPMENT 54
NANOPARTICLE RESEARCH COLLABORATIVE PROGRAMS 56
TABLE 21 ETPN STRATEGIC RESEARCH AND INNOVATION AGENDA 56
CHAPTER 8 NANOPARTICLES IN DRUG DEVELOPMENT AND FORMULATION 59
TABLE 22 NANOPARTICLES IN DRUG DEVELOPMENT APPLICATIONS 59
BIOSEPARATIONS 59
TABLE 23 MONOCLONAL ANTIBODY (MAB) DRUGS WITH POTENTIAL FOR USE IN
NANOPARTICLE DELIVERY SYSTEMS 60
RAPID DRUG ANALYSIS 62
REMOVAL OF IMPURITIES AND TOXINS 62
USING NANOPARTICLES TO INCORPORATE INSOLUBLE DRUGS 63
TABLE 24 SOLID LIPID NANOPARTICLE-REFORMATTED DRUGS 64
GOLD AND SILVER NANOPARTICLES IN BIOMEDICINE 64
DNA NANOPARTICLE DEVELOPMENT OF DNA-SPECIFIC DRUGS 65
CHAPTER 9 NANOPARTICLES IN DRUG DELIVERY SYSTEMS 68
NANOPARTICLES IN DRUG DELIVERY APPLICATIONS 68
TABLE 25 NANOPARTICLES IN DRUG DELIVERY APPLICATIONS 68
DESIGNING A NANOPARTICLE DRUG DELIVERY SYSTEM 69
NANOPARTICLE DRUG STABILITY 69
SIZE HOMOGENEITY OF NANOPARTICLE PREPARATIONS 70
DRUG LOADING OF NANOPARTICLES 71
DRUG RELEASE FROM NANOPARTICLE 71
EXTERNAL TRIGGERS FOR RELEASING DRUG FROM NANOPARTICLES 72
BINDING/INCORPORATION OF BIOMOLECULES TO NANOPARTICLES 72
NANOPARTICLE TOXICITY 74
LARGE-SCALE MANUFACTURING 75
METHODS OF ADMINISTRATION OF NANOPARTICLE DRUGS 77
TABLE 26 STANDARD ROUTES OF DRUG ADMINISTRATION 77
ORAL ADMINISTRATION 77
INJECTION ADMINISTRATION 78
TRANSDERMAL PATCH 78
TABLE 27 NANOPARTICLE TRANSDERMAL PATCH PRODUCTS 78
IMPLANTATION ADMINISTRATION 79
INHALATION ADMINISTRATION 80
NANOPARTICLES SUITABLE FOR DRUG DELIVERY SYSTEMS 80
TABLE 28 TYPES OF NANOPARTICLES SUPPLIED IN DRUG DELIVERY SYSTEMS 81
LIPID-BASED NANOPARTICLES 81
MICELLE NANOPARTICLES 82
DENDRIMER NANOPARTICLES 83
POLYMERIC NANOPARTICLES 83
METAL-BASED NANOPARTICLES 84
BIOLOGICAL MACROMOLECULE NANOPARTICLES 85
NANOCRYSTALS 86
TABLE 29 NANOCRYSTAL DRUGS APPROVED BY THE FDA 88
NANOPARTICLE DRUG DELIVERY SYSTEMS NOW AVAILABLE 89
ANTIBIOTIC NANOPARTICLES 89
ANTI-TUMOR AND SMALL MOLECULE DELIVERY BY NANOPARTICLE 90
RELEASE OF ANTI-CANCER DRUGS FROM NANOPARTICLES 95
BIOMACROMOLECULES DELIVERED BY NANOPARTICLES 97
NANOPARTICLE COATINGS FOR DRUG DELIVERY SYSTEMS 100
REMOVAL OF NANOPARTICLES FROM THE BODY 101
RENAL CLEARANCE 101
TABLE 30 MECHANISMS FOR REMOVAL OF NANOPARTICLES FROM THE BODY 102
CHAPTER 10 IN VITRO AND IN VIVO DIAGNOSTIC IMAGING 104
IN VITRO IMAGING 104
NANOPARTICLES IN DIAGNOSTIC IMAGING 104
TABLE 31 NANOPARTICLE CONTRAST MEDIA USED FOR IN VIVO DIAGNOSTIC
IMAGING 105
CHAPTER 11 BIOMEDICAL NANOPARTICLE PRODUCTS 109
FDA-APPROVED NANOPARTICLE DRUG DELIVERY SYSTEMS AND PRODUCTS 109
TABLE 32 CURRENT FDA-APPROVED NANOPARTICLE DRUG DELIVERY SYSTEMS 109
TABLE 33 FDA-APPROVED DRUGS FOR CANCER TREATMENT 111
TABLE 34 FDA-APPROVED DRUGS FOR CENTRAL NERVOUS SYSTEM DISEASES 113
TABLE 35 FDA-APPROVED NANOPARTICLE DRUGS FOR INFECTIOUS DISEASES 113
MAJOR PLAYERS IN NANOPARTICLE DRUG DELIVERY SYSTEMS 114
TABLE 36 MAJOR PLAYERS IN NANOPARTICLE DRUG DEVELOPMENT AND
FORMULATION MARKET 114
COMPANY PIPELINES FOR NANOPARTICLE DRUG DELIVERY 115
TABLE 37 COMPANY PIPELINE FOR CARDIOVASCULAR NANOPARTICLE DRUGS 115
TABLE 38 COMPANY PIPELINE FOR CNS DISEASE NANOPARTICLE DRUGS 118
TABLE 39 COMPANY PIPELINE FOR GI DISEASE NANOPARTICLE DRUGS 119
TABLE 40 COMPANY PIPELINE FOR INFECTIOUS DISEASE NANOPARTICLE DRUGS 120
TABLE 41 COMPANY PIPELINE FOR CANCER NANOPARTICLE DRUGS 123
TABLE 42 COMPANY PIPELINE FOR OPHTHALMIC NANOPARTICLE DRUGS 126
TABLE 43 COMPANY PIPELINE FOR AUTOIMMUNE DISEASE NANOPARTICLE DRUGS 128
DRIVERS OF NANOPARTICLE PRODUCTS AND MARKETING 129
LIMITERS OF NANOPARTICLE PRODUCT DEVELOPMENT AND MARKETING 129
CHAPTER 12 GLOBAL MARKET FOR NANOPARTICLE DRUGS AND DELIVERY SYSTEMS 132
THE GLOBAL MARKET 132
TABLE 44 GLOBAL MARKET FOR NANOPARTICLE DRUG DEVELOPMENT AND
FORMULATION AND DRUG DELIVERY SYSTEMS, THROUGH 2019 ($ MILLIONS) 132
TABLE 45 REGIONAL MARKET FOR NANOPARTICLE DRUG DEVELOPMENT AND
FORMULATION AND DRUG DELIVERY SYSTEMS, THROUGH 2019 ($ MILLIONS) 133
TABLE 46 GLOBAL MARKET FOR DIAGNOSTIC IMAGING AND IN VITRO IMAGING,
THROUGH 2019 ($ MILLIONS) 134
CHAPTER 13 CLINICAL TRIALS OF NANOPARTICLE DRUGS AND DRUG DELIVERY
SYSTEMS 136
TABLE 47 DISTRIBUTION OF NANOPARTICLE DRUG CLINICAL TRIALS WITHIN
DISEASE CATEGORIES 136
TABLE 48 CLINICAL TRIALS FOR NANOPARTICLE DRUGS FOR CANCER 137
TABLE 49 CLINICAL TRIALS FOR NANOPARTICLE DRUGS/PROCEDURES
(NON-CANCER) 148
TABLE 50 CLINICAL TRIALS WITH NANOPARTICLE DRUGS (MISCELLANEOUS) 151
TABLE 51 RESPIRATORY SYNCYTIAL VIRUS NANOPARTICLE VACCINE CLINICAL
TRIALS 152
TABLE 52 CLINICAL TRIALS FOR NANOPARTICLES FOR DIAGNOSTIC IMAGING 152
NANOPARTICLE DRUGS IN PRECLINICAL TESTING STAGE 153
TABLE 53 NANOPARTICLE DRUGS/CARRIERS IN PRECLINICAL EVALUATION 153
CHAPTER 14 PATENTS, LICENSING, MERGERS AND ACQUISITIONS 160
TABLE 54 MAJOR LICENSING, COLLABORATIVE PARTNERSHIPS AND MERGER AND
ACQUISITION ACTIVITIES 160
NANOPARTICLE PATENTS 162
TABLE 55 GLOBAL PERCENTAGE OF PATENTS ISSUED BY GEOGRAPHY, THROUGH
2014 163
U.S. PATENTS FOR NANOPARTICLES DRUG DEVELOPMENT AND DELIVERY 163
TABLE 56 U.S. PATENTS FOR NANOPARTICLE DRUG DEVELOPMENT AND DELIVERY 163
TABLE 57 U.S. PATENTS FOR NANOCRYSTALLINE DRUGS 167
QUANTUM DOT PATENTS 168
TABLE 58 U.S. PATENTS FOR QUANTUM DOT TECHNOLOGY APPLIED TO MEDICAL
APPLICATIONS 169
CHAPTER 15 COMPANY PROFILES 171
ABRAXIS BIOSCIENCES, INC 171
PRODUCTS 171
STRATEGY 172
ACCESS PHARMA INC. 172
PRODUCTS 172
STRATEGY 173
ADVANCELL 173
STRATEGY 173
ALKERMES, PLC 173
PRODUCTS 174
STRATEGY 174
ALNYLAM PHARMACEUTICALS INC. 174
PRODUCTS 175
STRATEGY 175
AMAG PHARMACEUTICALS INC. 175
PRODUCTS 176
STRATEGY 176
ASTRAZENECA PHARMACEUTICALS, PLC 176
PRODUCTS 177
STRATEGY 177
BIND BOSCIENCES INC. 177
STRATEGY 178
CALGENE CORP. 178
STRATEGY 179
CAMURUS AB 179
STRATEGY 179
CAPSULATION AG 180
STRATEGY 180
CERAMISPHERE PTY LTD 180
STRATEGY 181
CERULEAN PHARMA INC. 181
STRATEGY 182
CYTIMMUNE SCIENCES 182
PRODUCTS 183
STRATEGY 183
DEBIOTECH, S.A. 183
PRODUCTS 184
STRATEGY 184
ELAN PHARMACEUTICALS INC. 185
PRODUCTS 186
STRATEGY 186
ENSEMBLE THERAPEUTICS 186
STRATEGY 187
FLAMEL TEHNOLOGIES, INC 187
PRODUCTS 188
STRATEGY 188
GE GLOBAL RESEARCH 188
STRATEGY 189
MAGFORCE NANOTECHNOLOGIES AG 189
PRODUCTS 190
STRATEGY 190
MERSANA THERAPEUTICS INC. 190
PRODUCTS 191
STRATEGY 192
MIV THERAPEUTICS INC 192
STRATEGY 193
NANOCARRIER CO., LTD. 193
PRODUCTS 194
STRATEGY 194
NANOFIBER SOLUTIONS 194
PRODUCTS 195
NANO INTERFACE TECHNOLOGY, INC 195
PRODUCTS 195
STRATEGY 196
NANO MED TECH 196
PRODUCTS 196
NANOPROBES, INC 197
STRATEGY 197
NANOSPHERE INC. 198
PRODUCTS 198
STRATEGY 199
NANOTHERAPEUTICS 199
STRATEGY 200
NOVARTIS INTERNATIONAL AG 200
PRODUCTS 201
STRATEGY 201
PHARMASOL CORP. 201
PRODUCTS 202
STRATEGY 202
SKYEPHARMA, PLC 202
PRODUCTS 203
STRATEGY 204
STARPHARMA HOLDINGS, LTD 204
PRODUCTS 204
STRATEGY 205
T2 BIOSYSTEMS INC. 205
PRODUCTS 205
PRODUCTS 206
STRATEGY 206
TALON THERAPEUTICS INC. 206
PRODUCTS 207
STRATEGY 207
LIST OF TABLES
SUMMARY TABLE GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND
PHARMACEUTICALS, THROUGH 2019 ($ MILLIONS) 8
TABLE 1 DESCRIPTION OF NANOPARTICLES USED IN DRUG DELIVERY AND
DIAGNOSTIC IMAGING 12
TABLE 2 APPLICATION OF NANOPARTICLES IN BIOTECHNOLOGY 15
TABLE 3 APPLICATION OF NANOPARTICLES IN DRUG DEVELOPMENT 16
TABLE 4 APPLICATION OF NANOPARTICLES IN DRUG DELIVERY SYSTEMS 17
TABLE 5 NANOPARTICLE DRUG DELIVERY SYSTEMS 18
TABLE 6 NANOPARTICLES USED FOR IN VIVO DIAGNOSTIC IMAGING 20
TABLE 7 MAJOR PLAYERS IN NANOPARTICLE DRUG FIELD 21
TABLE 8 MAJOR PLAYER COMPANY REVENUES FOR NANOPARTICLE DRUGS,
THROUGH 2019 ($ MILLIONS) 22
TABLE 9 MAJOR NANOPARTICLE/NANOCRYSTAL DRUG REVENUES, THROUGH 2014 23
TABLE 10 GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND
PHARMACEUTICALS, THROUGH 2019 ($ MILLIONS) 25
TABLE 11 GLOBAL REVENUES BIOTECHNOLOGY APPLICATIONS OF NANOPARTICLES,
THROUGH 2019 ($ MILLIONS) 26
TABLE 12 GLOBAL MARKET FOR NANOPARTICLES IN DRUG DEVELOPMENT AND
FORMULATION, THROUGH 2019 ($ MILLIONS) 27
TABLE 13 GLOBAL REVENUES FROM NANOPARTICLES IN DRUG DELIVERY SYSTEMS,
THROUGH 2019 ($ MILLIONS) 28
TABLE 14 GLOBAL REVENUES FROM NANOPARTICLES IN DIAGNOSTIC IMAGING
SYSTEMS, THROUGH 2019 ($ MILLIONS) 29
TABLE 15 GLOBAL DISTRIBUTION OF NANOBIOTECHNOLOGY AND NANOMEDICINE
COMPANIES 29
TABLE 16 NANOPARTICLE STRUCTURE AND PROPERTIES 33
TABLE 17 NANOPARTICLE SYSTEMS APPROVED FOR DRUG DELIVERY 37
TABLE 18 SAMPLE OF DRUGS DELIVERED THROUGH LIPOSOME NANOTECHNOLOGY 43
TABLE 19 NANOPARTICLES IN BIOTECHNOLOGY APPLICATIONS 49
TABLE 20 NANOBIOSENSOR TECHNOLOGY UNDER DEVELOPMENT 54
TABLE 21 ETPN STRATEGIC RESEARCH AND INNOVATION AGENDA 56
TABLE 22 NANOPARTICLES IN DRUG DEVELOPMENT APPLICATIONS 59
TABLE 23 MONOCLONAL ANTIBODY (MAB) DRUGS WITH POTENTIAL FOR USE IN
NANOPARTICLE DELIVERY SYSTEMS 60
TABLE 24 SOLID LIPID NANOPARTICLE-REFORMATTED DRUGS 64
TABLE 25 NANOPARTICLES IN DRUG DELIVERY APPLICATIONS 68
TABLE 26 STANDARD ROUTES OF DRUG ADMINISTRATION 77
TABLE 27 NANOPARTICLE TRANSDERMAL PATCH PRODUCTS 78
TABLE 28 TYPES OF NANOPARTICLES SUPPLIED IN DRUG DELIVERY SYSTEMS 81
TABLE 29 NANOCRYSTAL DRUGS APPROVED BY THE FDA 88
TABLE 30 MECHANISMS FOR REMOVAL OF NANOPARTICLES FROM THE BODY 102
TABLE 31 NANOPARTICLE CONTRAST MEDIA USED FOR IN VIVO DIAGNOSTIC
IMAGING 105
TABLE 32 CURRENT FDA-APPROVED NANOPARTICLE DRUG DELIVERY SYSTEMS 109
TABLE 33 FDA-APPROVED DRUGS FOR CANCER TREATMENT 111
TABLE 34 FDA-APPROVED DRUGS FOR CENTRAL NERVOUS SYSTEM DISEASES 113
TABLE 35 FDA-APPROVED NANOPARTICLE DRUGS FOR INFECTIOUS DISEASES 113
TABLE 36 MAJOR PLAYERS IN NANOPARTICLE DRUG DEVELOPMENT AND
FORMULATION MARKET 114
TABLE 37 COMPANY PIPELINE FOR CARDIOVASCULAR NANOPARTICLE DRUGS 115
TABLE 38 COMPANY PIPELINE FOR CNS DISEASE NANOPARTICLE DRUGS 118
TABLE 39 COMPANY PIPELINE FOR GI DISEASE NANOPARTICLE DRUGS 119
TABLE 40 COMPANY PIPELINE FOR INFECTIOUS DISEASE NANOPARTICLE DRUGS 120
TABLE 41 COMPANY PIPELINE FOR CANCER NANOPARTICLE DRUGS 123
TABLE 42 COMPANY PIPELINE FOR OPHTHALMIC NANOPARTICLE DRUGS 126
TABLE 43 COMPANY PIPELINE FOR AUTOIMMUNE DISEASE NANOPARTICLE DRUGS 128
TABLE 44 GLOBAL MARKET FOR NANOPARTICLE DRUG DEVELOPMENT AND
FORMULATION AND DRUG DELIVERY SYSTEMS, THROUGH 2019 ($ MILLIONS) 132
TABLE 45 REGIONAL MARKET FOR NANOPARTICLE DRUG DEVELOPMENT AND
FORMULATION AND DRUG DELIVERY SYSTEMS, THROUGH 2019 ($ MILLIONS) 133
TABLE 46 GLOBAL MARKET FOR DIAGNOSTIC IMAGING AND IN VITRO IMAGING,
THROUGH 2019 ($ MILLIONS) 134
TABLE 47 DISTRIBUTION OF NANOPARTICLE DRUG CLINICAL TRIALS WITHIN
DISEASE CATEGORIES 136
TABLE 48 CLINICAL TRIALS FOR NANOPARTICLE DRUGS FOR CANCER 137
TABLE 49 CLINICAL TRIALS FOR NANOPARTICLE DRUGS/PROCEDURES
(NON-CANCER) 148
TABLE 50 CLINICAL TRIALS WITH NANOPARTICLE DRUGS (MISCELLANEOUS) 151
TABLE 51 RESPIRATORY SYNCYTIAL VIRUS NANOPARTICLE VACCINE CLINICAL
TRIALS 152
TABLE 52 CLINICAL TRIALS FOR NANOPARTICLES FOR DIAGNOSTIC IMAGING 152
TABLE 53 NANOPARTICLE DRUGS/CARRIERS IN PRECLINICAL EVALUATION 153
TABLE 54 MAJOR LICENSING, COLLABORATIVE PARTNERSHIPS AND MERGER AND
ACQUISITION ACTIVITIES 160
TABLE 55 GLOBAL PERCENTAGE OF PATENTS ISSUED BY GEOGRAPHY, THROUGH
2014 163
TABLE 56 U.S. PATENTS FOR NANOPARTICLE DRUG DEVELOPMENT AND DELIVERY 163
TABLE 57 U.S. PATENTS FOR NANOCRYSTALLINE DRUGS 167
TABLE 58 U.S. PATENTS FOR QUANTUM DOT TECHNOLOGY APPLIED TO MEDICAL
APPLICATIONS 169
LIST OF FIGURES
SUMMARY FIGURE GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND
PHARMACEUTICALS, 2012-2019 ($ MILLIONS) 8

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Nanomaterials Market by Type and End-user - Global Opportunity Analysis and Industry Forecast, 2014 - 2022

Nanomaterials Market by Type and End-user - Global Opportunity Analysis and Industry Forecast, 2014 - 2022

  • $ 4920
  • Industry report
  • September 2016
  • by Allied Market Research

Nanomaterials possess nanoscale dimensions ranging from 1 to 100 nanometers. They occur naturally or can be engineered with specific properties such as size, shape, surface, and chemistry. Volcanic ash ...

Nanomaterials - Global Market Outlook (2016-2022)

Nanomaterials - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • November 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Nanomaterials Market accounted for $4.79 billion in 2015 and is expected to reach $19.83 billion by 2022 growing at a CAGR of 22.5% from 2015 to 2022. The nanomaterials ...

North America NanoSensors Market - Growth, Trends and Forecasts (2015- 2020)

North America NanoSensors Market - Growth, Trends and Forecasts (2015- 2020)

  • $ 3850
  • Industry report
  • August 2016
  • by Mordor Intelligence LLP

The North America Nano Sensors market is expected to increase to $238.13 Million by 2020 at a CAGR of 93.71% over the period 2014-2020. As North America is a matured market when considering the technological ...


Download Unlimited Documents from Trusted Public Sources

Protein Industry in South Africa

  • September 2016
    29 pages
  • Protein  

    Cancer  

    Therapy  

  • South Africa  

View report >

Protein and Enzyme Industry in Poland

  • July 2016
    222 pages
  • Protein  

    Enzyme  

    Biotechnology  

  • Poland  

View report >

Biotech Industry in Brazil

  • July 2016
    42 pages
  • Biotech  

    Pharmaceutical  

  • Brazil  

    South America  

View report >

Enzyme Supply

11 months ago

Related Market Segments :

Nanobiotechnology
Nanoparticle

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.